This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
$1 buys you full access to ALL of TheStreet's Subscription Services! Learn More

Hemispherx Announces New Publication With Potential Insight Into High Mortality Rate In Middle Eastern Respiratory Syndrome (MERS)

Stocks in this article: HEB

PHILADELPHIA, June 16, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE:HEB) announced that a new publication (June 2, 2014) in the Formulary Journal ( http://formularyjournal.modernmedicine.com/formulary-journal/news/mers-interferoninnate-immune-deficiency-state-continues-surge?page=full ) suggests that the high pathogenicity of MERS may be due, in part, to an innate immune deficiency state that results secondary to inhibition of a first responder to viral infection, interferon (IFN), at an early step in MERS infection. The article, " MERS, an interferon innate immunity state, continues to surge" is authored by Hemispherx scientists and affiliates. The authors suggest that correcting the defect in immunity may be the first significant way to decrease MERS-associated mortality.

More recently, there has been a dramatic, non-Ramadan associated, increase in new cases of MERS. Ramadan will begin on June 29 th, 2014, and 19 countries have now identified MERS cases.

MERS-CoV and SARS-CoV (Severe Acute Respiratory Syndrome) viruses are members of the same virus family-termed coronavirus. Only MERS and SARS have high mortality rates in man as the other four human coronavirus family members are generally associated with mild, non-life-threatening, common cold symptoms. Only the MERS virus and SARS inhibit the production of a key component of human immunity, IFN. IFN has been previously established as necessary to fight off a number of otherwise lethal viral infections.

Recent Hemispherx collaborations with the National Institutes of Health (NIH), specifically National Institutes of Allergy and Infectious Disease (NIAID), using human cells in culture suggest that Alferon® N may be effective either as a preventative or treatment of early MERS infection ( http://www.hemispherx.net/content/investor/default.asp?goto=781). Subsequently, similar positive inhibitory results with Alferon® N were obtained at the University of Texas ( http://www.hemispherx.net/content/investor/default.asp?goto=786).

Treatment late in the course of human highly lethal coronaviral infections (MERS/SARS) is unlikely to alter the diseases course as, by then, the host immune system has already been severely disabled. Going forward, clinical protocols will need to be established to evaluate various systemically therapeutic options rather than by isolated treatments of certain infected individuals as are currently employed.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,827.75 +12.81 0.07%
S&P 500 2,072.83 +5.80 0.28%
NASDAQ 4,787.3170 +29.0650 0.61%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs